Cargando…
A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma
We conducted a prospective phase I study to evaluate safety of an orally administered Salmonella encoding IL‐2 (SalpIL2) in combination with amputation and adjuvant doxorubicin for canine appendicular osteosarcoma. Efficacy was assessed as a secondary measure. The first dose of SalpIL2 was administe...
Autores principales: | Fritz, Sara E., Henson, Michael S., Greengard, Emily, Winter, Amber L., Stuebner, Kathleen M., Yoon, Una, Wilk, Vicki L., Borgatti, Antonella, Augustin, Lance B., Modiano, Jaime F., Saltzman, Daniel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645873/ https://www.ncbi.nlm.nih.gov/pubmed/29067193 http://dx.doi.org/10.1002/vms3.32 |
Ejemplares similares
-
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
por: Sorenson, Brent S, et al.
Publicado: (2011) -
Changes in antimicrobial resistance in Salmonella enterica serovar typhimurium.
por: Angulo, F J, et al.
Publicado: (2000) -
Polyamines Are Required for Virulence in Salmonella enterica Serovar Typhimurium
por: Jelsbak, Lotte, et al.
Publicado: (2012) -
sRNAs and the virulence of Salmonella enterica serovar Typhimurium
por: Hébrard, Magali, et al.
Publicado: (2012) -
Salmonella enterica Serovar Typhimurium Strategies for Host Adaptation
por: Anderson, Christopher J., et al.
Publicado: (2017)